Integrated BioPharma Reports Results for its Quarter Ended March 31, 2025
- Revenue growth of 6.1% YoY in Q3 2025
- Operating income increased to $0.7M from $0.4M YoY
- Net income doubled to $0.6M in Q3 2025 from $0.3M in Q3 2024
- Successfully expanded customer base, reducing concentration risk from top customers (83% vs 90%)
- Turned around nine-month operating loss of $0.2M to $1.4M profit
- High customer concentration with two clients representing 83% of revenue
- Relatively modest profit margins with $0.02 EPS
HILLSIDE, NJ / ACCESS Newswire / May 14, 2025 / Integrated BioPharma, Inc. ((OTCQX:INBP)) (the "Company" or "INBP") reports its financial results for the quarter ended March 31, 2025.
Revenue for the quarter ended March 31, 2025 was
Revenue for the nine-month period ended March 31, 2025 was
For the quarters ended March 31, 2025 and 2024, the Company had net income of approximately
For the nine-month periods ended March 31, 2025 and 2024, the Company had net income of approximately
"Our revenues increased by
A summary of our financial results for the three months and nine months ended March 31, 2025 and 2024 follows:
INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share amounts)
(Unaudited)
Three Months Ended | Nine Months Ended | |||||||||||||||
March 31, | March 31, | |||||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
Total revenue | $ | 13,947 | $ | 13,147 | $ | 40,178 | $ | 37,571 | ||||||||
Cost of sales | 12,396 | 11,899 | 36,085 | 34,971 | ||||||||||||
Gross profit | 1,551 | 1,248 | 4,093 | 2,600 | ||||||||||||
Selling and administrative expenses | 812 | 893 | 2,662 | 2,751 | ||||||||||||
Operating income (loss) | 739 | 355 | 1,431 | (151 | ) | |||||||||||
Other income (expense), net | 39 | (3 | ) | 36 | 5 | |||||||||||
Income (loss) before income taxes | 778 | 352 | 1,467 | (146 | ) | |||||||||||
Income tax expense, net | 167 | 67 | 481 | 10 | ||||||||||||
Net income (loss) | $ | 611 | $ | 285 | $ | 986 | $ | (156 | ) | |||||||
Net income (loss) per share: | ||||||||||||||||
Basic | $ | 0.02 | $ | 0.01 | $ | 0.03 | $ | (0.01 | ) | |||||||
Diluted | $ | 0.02 | $ | 0.01 | $ | 0.03 | $ | (0.01 | ) | |||||||
Weighted average common shares outstanding: | ||||||||||||||||
Basic | 30,300,720 | 30,099,610 | 30,190,869 | 30,054,883 | ||||||||||||
Diluted | 31,514,591 | 30,744,222 | 30,960,916 | 30,054,883 | ||||||||||||
About Integrated BioPharma Inc. (INBP)
Integrated BioPharma, Inc. ("INBP") is engaged primarily in the business of manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. Further information is available at ir.ibiopharma.com.
This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, as well as assumptions, that, if they never materialize or prove incorrect, could cause the results of INBP to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements generally are identified by the words "expects," "anticipates," believes," intends," "estimates," "should," "would," "strategy," "plan" and similar expressions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements and are not guarantees of future performance. Such statements speak only as of the date hereof, are subject to change and should not be relied upon for investment purposes. INBP undertakes no obligation to revise or update any statements for any reasons. The risks, uncertainties and assumptions include, among others, changes in general economic and business conditions; loss of market share through competition; introduction of competing products by other companies; the timing of regulatory approval and the introduction of new products by INBP; changes in industry capacity; pressure on prices from competition or from purchasers of INBP's products; regulatory changes in the pharmaceutical manufacturing industry and nutraceutical industry; regulatory obstacles to the introduction of new technologies or products that are important to INBP; availability of qualified personnel; the loss of any significant customers or suppliers; inflation, including inflationary pressures from any tariffs, and tightened labor markets; our ability to expand our customer base and other risks and uncertainties described in the section entitled "Risk Factors" in INBP's most recent Annual Report on Form 10-K and its subsequent Quarterly Reports on Form 10-Q. Accordingly, INBP cannot give assurance that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of INBP.
Contact:
Dina Masi, CFO
Integrated BioPharma, Inc.
investors@ibiopharma.com
888.319.6962
SOURCE: Integrated BioPharma, Inc.
View the original press release on ACCESS Newswire
FAQ
What was Integrated BioPharma's (INBP) revenue in Q3 2025?
How much did INBP earn per share in Q3 2025?
What percentage of INBP's revenue comes from its top customers?
How much operating income did INBP generate in Q3 2025?
What was INBP's net income for the nine months ended March 31, 2025?
